Hansa Biopharma partners with Cradle on AI-driven protein design platform

• Hansa Biopharma entered a collaboration with Cradle to deploy an AI protein-design platform across its R&D programs.
• Partnership targets faster design, optimization, development of new immunomodulatory drug candidates for severe autoimmune diseases.
• Cradle platform supports hit identification, multi-parameter optimization, active learning from Hansa data to improve predictability in lab-in-the-loop workflows.
• Hansa flagged Cradle customer results of up to 18 months shorter development timelines, implying potential R&D savings per candidate.
• Deal aligns with Hansa’s strategy to expand AI-driven drug development while advancing its IgG-cleaving enzyme pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202610010200BITN____UKPR__SV_20260930-BIT-7567-0) on October 01, 2026, and is solely responsible for the information contained therein.